Business
Allergy Therapeutics at Cowen Health Conference
Allergy Therapeutics at Cowen Health Conference.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 9402D\n Allergy Therapeutics PLC\n 08 March 2022\n \n \n \n \n \n \n \n \n Al\n \n \n l\n \n \n ergy Therapeutics plc\n \n \n \n (\"\n A\n l\n l\n ergy Therapeutics\", the \"Group\" or \"Company\")\n \n \n \n \n \n Allergy Therapeutics to Present at the Cowen 42nd Annual Health Care Conference \n \n \n \n \n \n \n 8 March 2022\n \n Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company\n \n \n specialising in allergy vaccines, today announces that Manuel Llobet, Chief Executive Officer, Nick Wykeman,\n \n \n Chief Financial Officer, and Alan Bullimore, Head of Business Innovation of Allergy Therapeutics, will present at the Cowen 42nd Annual Health Care Conference taking place from 07-09 March 2022. \n \n \n \n \n \n The presentation will review data supporting the upcoming clinical trials for the Group's lead pipeline candidates including Grass MATA MPL, which is expected to enter Phase III development in Q3 2022, and VLP Peanut, which is on track to enter the clinic in the Phase I PROTECT trial later this year. \n \n \n \n \n \n A replay of the presentation will be made available under the 'Investors' section on Allergy Therapeutics'\n \n \n website at \n \n www.allergytherapeutics.com/investors/results-reports-and-presentations/\n \n .\n \n \n \n \n \n - ENDS -\n \n \n \n \n \n \n \n \n For further information, please contact:\n \n \n \n \n \n Allergy Therapeutics\n \n \n +44 (0) 1903 845 820\n \n \n Manuel Llobet, Chief Executive Officer\n \n \n Nick Wykeman, Chief Financial Officer\n \n \n \n \n \n Panmure Gordon\n \n \n +44 (0) 20 7886 2500\n \n \n Freddy Crossley, Emma Earl, Corporate Finance\n \n \n Rupert Dearden, Corporate Broking\n \n \n \n \n \n Consilium Strategic Communications\n \n \n +44 20 3709 5700\n \n \n Mary-Jane Elliott / David Daley / Davide Salvi\n \n \n \n [email protected]\n \n \n \n \n \n \n Stern Investor Relations, Inc.\n \n \n +1 212 362 1200\n \n \n Christina Tartaglia\n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n Notes for editors:\n \n \n \n \n \n About Allergy Therapeutics\n \n \n \n \n \n Allergy Therapeutics is an international commercial biotechnology company foc...